白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2014年
10期
611-615
,共5页
陈珵%魏道林%王椿%蔡琦%高彦荣%赵初娴%赵旻%卫菊%朱骏
陳珵%魏道林%王椿%蔡琦%高彥榮%趙初嫻%趙旻%衛菊%硃駿
진정%위도림%왕춘%채기%고언영%조초한%조민%위국%주준
难治性淋巴瘤%培门冬酶%化疗%联合
難治性淋巴瘤%培門鼕酶%化療%聯閤
난치성림파류%배문동매%화료%연합
Refractory lymphoma%PEG-asparaginase%Chemotherapy%Combination
目的 观察培门冬酶联合化疗治疗难治性淋巴瘤的效果.方法 回顾性分析28例难治性淋巴瘤患者接受含培门冬酶化疗方案治疗的结果.结果 28例患者中位年龄36岁,治疗前疾病状态为部分缓解(PR)4例,疾病稳定(SD)6例,疾病复发或疾病进展(PD)18例,治疗后患者完全缓解(CR)5例,PR 15例,SD 4例,PD 4例,总有效(CR+PR)率为71.4%.16例T细胞性淋巴瘤患者治疗有效率达81.3%(13/16).10例弥漫大B细胞淋巴瘤患者治疗有效率达60.0%(6/10).治疗前无骨髓浸润者或无乳酸脱氢酶升高者治疗有效率更高.主要不良反应为骨髓抑制、消化道反应、凝血异常.结论 培门冬酶联合化疗方案可作为拯救性治疗难治性淋巴瘤的选择之一.
目的 觀察培門鼕酶聯閤化療治療難治性淋巴瘤的效果.方法 迴顧性分析28例難治性淋巴瘤患者接受含培門鼕酶化療方案治療的結果.結果 28例患者中位年齡36歲,治療前疾病狀態為部分緩解(PR)4例,疾病穩定(SD)6例,疾病複髮或疾病進展(PD)18例,治療後患者完全緩解(CR)5例,PR 15例,SD 4例,PD 4例,總有效(CR+PR)率為71.4%.16例T細胞性淋巴瘤患者治療有效率達81.3%(13/16).10例瀰漫大B細胞淋巴瘤患者治療有效率達60.0%(6/10).治療前無骨髓浸潤者或無乳痠脫氫酶升高者治療有效率更高.主要不良反應為骨髓抑製、消化道反應、凝血異常.結論 培門鼕酶聯閤化療方案可作為拯救性治療難治性淋巴瘤的選擇之一.
목적 관찰배문동매연합화료치료난치성림파류적효과.방법 회고성분석28례난치성림파류환자접수함배문동매화료방안치료적결과.결과 28례환자중위년령36세,치료전질병상태위부분완해(PR)4례,질병은정(SD)6례,질병복발혹질병진전(PD)18례,치료후환자완전완해(CR)5례,PR 15례,SD 4례,PD 4례,총유효(CR+PR)솔위71.4%.16례T세포성림파류환자치료유효솔체81.3%(13/16).10례미만대B세포림파류환자치료유효솔체60.0%(6/10).치료전무골수침윤자혹무유산탈경매승고자치료유효솔경고.주요불량반응위골수억제、소화도반응、응혈이상.결론 배문동매연합화료방안가작위증구성치료난치성림파류적선택지일.
Objective To evaluate the efficacy and safety of PEG-asparaginase based regimen for refractory lymphoma.Methods The retrospective analysis of twenty-eight patients who received PEGasparaginase based regimen.Results Twenty-eight patients were eligible for treatment-response evaluation.The median age was 36 years old.Before treatment,4 patients were in partial response,6 patients in stable disease,and 18 patients in progressive disease.After treatment,5 patients were in complete response (CR),15 patients were in partial response (PR),4 patients were in stable disease,and 4 patients were in progressive disease.The overall response (CR+PR) rate was 71.4 %.The treatment effective rate was 81.3 % (13/16) in 16 cases of T-cell lymphoma and 60.0 % (6/10) in diffuse large B-cell lymphoma.The treatment rate was higher for patients without bone marrow infiltration or without increased dehydrogenase.The major adverse events were myelosuppression,gastrointestinal reaction and coagulopathy.Conclusion PEG-asparaginase based regimen was one of the options of salvage therapy for refractory lymphoma.